Stocktoria
GeneDx Holdings Corp. WGS
Nasdaq · stock · Services-Health Services · website · IPO 2020-09-04
GeneDx Holdings Corp. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $427.5M | $305.4M | $202.6M | $234.7M | $212.2M | $179.3M |
| Gross profit | $298.2M | $194.4M | $90.0M | -$26.8M | -$16.6M | $4.0M |
| R&D expense | $72.0M | $45.7M | $58.3M | $86.2M | $105.2M | $72.7M |
| Operating income | -$13.1M | -$23.2M | -$180.6M | -$667.7M | -$446.1M | -$242.0M |
| Interest expense | — | — | — | $3.2M | $2.8M | $2.5M |
| Income tax | -$116,000 | -$343,000 | -$926,000 | -$49.1M | $0 | $0 |
| Net income | -$21.0M | -$52.3M | -$175.8M | -$549.0M | -$245.4M | -$241.3M |
| EPS (diluted) | $-0.73 | $-1.94 | $-7.23 | $-53.63 | $-2.27 | $-47036.00 |
| Operating cash flow | $33.3M | -$28.5M | -$180.1M | -$319.2M | -$190.4M | -$93.1M |
| Free cash flow | $14.3M | -$34.0M | -$185.4M | -$326.3M | -$199.8M | -$117.2M |
| Cash & equivalents | $105.0M | $85.2M | $99.7M | $123.9M | $400.6M | $108.1M |
| Inventory | $14.0M | $10.7M | $8.8M | $13.7M | $33.5M | $25.0M |
| Total assets | $523.7M | $419.4M | $418.8M | $490.9M | $554.1M | $251.6M |
| Total liabilities | $215.5M | $174.1M | $190.7M | $237.2M | $166.0M | $247.3M |
| Shareholders' equity | $308.2M | $245.2M | $228.0M | $253.7M | $388.1M | -$330.1M |
Growth · year-over-year · Revenue CAGR 19%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | +40.0% | +50.8% | -13.7% | +10.6% | +18.3% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.